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Abstract
Background: Because they can generate comparable predictions, mathematical models are ideal tools for evaluating
alternative drug or vaccine allocation strategies. To remain credible, however, results must be consistent. Authors of a
recent assessment of possible influenza vaccination strategies conclude that older children, adolescents, and young adults
are the optimal targets, no matter the objective, and argue for vaccinating them. Authors of two earlier studies concluded,
respectively, that optimal targets depend on objectives and cautioned against changing policy. Which should we believe?
Methods and Findings: In matrices whose elements are contacts between persons by age, the main diagonal always
predominates, reflecting contacts between contemporaries. Indirect effects (e.g., impacts of vaccinating one group on
morbidity or mortality in others) result from off-diagonal elements. Mixing matrices based on periods in proximity with
others have greater sub- and super-diagonals, reflecting contacts between parents and children, and other off-diagonal
elements (reflecting, e.g., age-independent contacts among co-workers), than those based on face-to-face conversations. To
assess the impact of targeted vaccination, we used a time-usage study’s mixing matrix and allowed vaccine efficacy to vary
with age. And we derived mortality rates either by dividing observed deaths attributed to pneumonia and influenza by
average annual cases from a demographically-realistic SEIRS model or by multiplying those rates by ratios of (versus adding
to them differences between) pandemic and pre-pandemic mortalities.
Conclusions: In our simulations, vaccinating older children, adolescents, and young adults averts the most cases, but
vaccinating either younger children and older adults or young adults averts the most deaths, depending on the age
distribution of mortality. These results are consistent with those of the earlier studies.
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Introduction
Seasonal influenza causes an estimated 200,000 hospitalizations
and 36,000 deaths on average in the United States, most among
the elderly [1]. If a 1918-like pandemic occurred today, 10 million
hospitalizations and 1.9 million deaths – many among younger
adults – are expected [2]. Vaccination affords the best protection,
especially for those at risk of pneumonia and other life-threatening
complications [1].
Development and production of influenza vaccines is challeng-
ing. In the northern hemisphere, the World Health Organization
(WHO) collects relevant information every February for review by
experts. Based on which viruses they believe will most likely be
circulating, the experts select 3 strains for inclusion in the
upcoming season’s vaccine. Almost every year, at least one
vaccine constituent is replaced, because viral strains drift; i.e.,
undergo constant genetic change. Even small changes can result in
novel strains, and mismatch with circulating strains can reduce
vaccine effectiveness, as occurred during the 2007–08 influenza
season [3]. Once the experts have identified the strains likely to
circulate next season, a vaccine must be manufactured in a slow
process that has changed little since its invention. Testing,
approval, and distribution also take several months. Problems
encountered during production, such as inability to grow sufficient
quantities of a viral strain, may cause vaccine shortages or delays
in distribution. Such problems have affected vaccine availability in
recent influenza seasons in the United States [4].
During influenza pandemics, these challenges are compounded.
Pandemic strains may emerge when antigenic shifts – major
changes in the genetic makeup of a virus – occur in influenza A,
creating new viral subtypes against which populations have little or
no immunity [5]. Even when effective vaccines are created, acute
shortages are possible, especially in areas with limited production
capacity that also have little advance warning, making it difficult
or impossible to obtain sufficient vaccine in time to protect at-risk
populations. During the recent pandemic, even in wealthy
countries that developed and produced an H1N1 vaccine as soon
as possible, vaccine supplies were inadequate to accommodate all
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motivated health authorities in influenza vaccine-producing
countries to devise strategies for ensuring that people who were
most likely to suffer complications of influenza were vaccinated
first. In the United States, the CDC’s Advisory Committee on
Immunization Practices (ACIP) determined that pregnant women,
caregivers of young infants, health care workers, and people too
young to have antibodies to H1N1 had first priority. Next were
those most vulnerable to complications of influenza, generally the
elderly [6].
In such circumstances, other strategies for using scarce influenza
vaccine efficiently also warrant consideration. Among such
strategies is indirect protection; that is, immunizing those who
might infect vulnerable people. One group whose vaccination
might achieve the benefits of indirect protection is schoolchildren.
The merits of vaccinating schoolchildren against influenza, partly
to protect others, such as the elderly, have been argued from
community-intervention trials [7], natural experiments [8], and
individual-based models [9]. While trials generally are better
controlled than natural experiments, they are relatively expensive
and time-consuming. Moreover, only models allow examination of
alternative vaccination strategies in exactly the same setting.
Models should be evaluated against historical observations to
check their predictive ability, but identifying and remedying
deficiencies of individual-based models can be prohibitively
difficult. Population models are simple enough for evaluation
before use to inform public policy making. Analytical results, such
as the optimal targets for interventions against infectious diseases,
also can be derived.
To identify vaccine allocation strategies with the greatest
potential to reduce influenza morbidity and mortality, we studied
an age-structured population model whose infection rates we
estimated from observed proportions infected [10] and interper-
sonal contacts weighted by duration [11]. Our model’s disease-
induced mortality rates were either quotients of deaths attributed
to pneumonia or influenza [12] and populations at risk or products
of those rates and ratios of 1918 and average 1913–17 mortalities
[13]. We refer to the latter as contemporary 1918-like mortality.
Methods
We adapted a demographically-realistic version of a classic
population model [14] with 4 disease or immune states:
susceptible; infected, but not yet infectious (exposed); infectious;
recovered and immune (removed). We added vaccination with
age-specific efficacy, based on the work of Govaert et al., who
conducted the only randomized, double-blind, placebo-controlled
trial of vaccination against morbidity [15], and loss of immunity to
circulating strains, via antigenic shifting and drifting [16]. For lack
of the requisite information, we ignored transient protection via
maternal antibodies, despite how important this protection may
be, given seasonal influenza complications among infants aged ,6
months [17]. For simplicity, we also ignored immigration and
emigration. File S1 and Table S1 describe the system of equations
and parameter values.
Age-structured models require multiple infection rates, to which
Anderson and May [18] referred collectively as ‘‘who-acquires-
infection-from-whom.’’ We derived ours from age-specific pro-
portions of household members infected during the 1957 influenza
pandemic [10], commonly called ‘‘attack rates,’’ and from
interpersonal contacts weighted by duration in Portland, Oregon
[11]. Briefly, the risks of infection, li~aibi
P
j cijyj, where ai are
average numbers of contacts per person per day; bi are
probabilities of infection upon contact with infectious persons; cij
are proportions of contacts that members of group i have with
those of group j; and yj=Ij/Nj are probabilities that randomly
encountered members of group j are infectious. Using a logistic
regression model fitted to the yi reported by Chin et al. [10] and
the duration-weighted contacts of Del Valle et al. [11], to-
gether with the relationships li~{ln 1{yi ðÞ and ai~
P
j Cij,
where Cij~aicij,w ee s t i m a t e dli and then bi.
Figure 7 of Glasser et al. [unpublished manuscript] illustrates bi
obtained using these ‘‘attack rates’’ and the Cij from several
recently published studies of face-to-face conversations or periods
in proximity with others during which respiratory diseases might
be transmitted. Del Valle et al. [11] not only weighted contacts by
duration, but the off-diagonal elements of their contact matrix are
relatively large, increasing possible indirect effects (e.g., impact of
vaccination on morbidity or mortality in groups not targeted), and
they kindly shared their observations. Thus, we could calculate
empirical rates of effective contact between members of any age
groups simply by averaging (Figure 1).
We calculated age-specific disease-induced mortalities as
quotients of 2005 deaths attributed to pneumonia or influenza
(Table S1) and simulated infections during an average year. We
obtained contemporary 1918-like mortalities by fitting logistic
regression models to published 1918 and average 1913–17 rates
[13], calculating age-specific ratios for the groups we modeled,
,1, 1–4, 5–9, …, 80–84, 85+ years (Figure 2a), and multiplying
them by the 2005 rates. Our estimates of mortality conditional on
influenza during 2005 and a hypothetical contemporary 1918-like
pandemic are illustrated in Figure 2b.
In experiments, all else should be equal. We simulated our
model without vaccination, with 60% of infants ,1 year and
adults $65 years of age or the same percentage of children aged
1–9, adolescents 10–19, or young adults 20–29 years being
vaccinated. These groups are roughly the same size, but coverage
actually is ,60% among persons ,65 years of age [19]. Our
hypothetical annual influenza vaccine protected 70% of people 1–
64 years of age, but lower proportions of infants and older adults.
Efficacy was 35% among infants and declined linearly with age
over 64 years (i.e., was 60% among people aged 65–69 years, 50%
among those aged 70–74 years, and so on). The resulting efficacies
among elderly adults correspond roughly to those reported by
Govaert et al. [15]. Annual vaccination occurred November
through January; pandemic vaccination began 30 days later and
continued for 6 months. Pandemic efficacy was half annual, but as
roughly twice as many doses were eventually administered, similar
numbers of people were protected.
To assess the impact of these alternative strategies on morbidity
and mortality, we averaged daily differences between age-specific
cases or deaths with and without vaccination over 365-day
periods. Averaging was necessary because our simulation model is
stochastic (i.e., we employ Renshaw’s discrete event/time method
[20]). Finally, in age-structured models, the average number of
effective contacts, R0, may be calculated as the dominant
eigenvalue of the next-generation matrix [21] whose associated
eigenvector describes the age-specific contributions [22,23]. We
derive these quantities in File S2.
Results
Our matrix of infection rates (Figure 1) illustrates preferential
mixing, not only among contemporaries – which is particularly
intense among older children, adolescents, and young adults [24] –
but also that between parents and children and among co-workers
evident in more recent, higher-resolution observations [11,25,26].
As indirect effects emanate from off-diagonal matrix elements,
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intervention impacts via transmission modeling. Similarly, our
1918-like mortalities (Figure 2) resemble those of the 2009
pandemic, although this swine H1N1 was much less virulent than
that avian strain.
During simulated pandemic as well as annual influenza
outbreaks, vaccinating older children, adolescents, and young
adults reduced morbidity the most, especially among target age
groups (Figures 3a and b). Despite a contact matrix with relatively
large off-diagonal elements, only 20–25% of cases averted were in
groups not targeted. By contrast, vaccinating infants and elderly
adults reduced mortality most during simulated annual influenza
outbreaks (Figure 4a), but vaccinating young adults also reduced
mortality during simulated pandemics (Figure 4b).
While target age groups are similar in size, the numbers of cases
averted depend on the vaccine efficacies as well as age distribution
of the 2005 U.S. population. Cases averted per efficacy adjusted
dose correspond to the proportionate contributions to R0
(Figure 5), which identifies the optimal target for interventions to
reduce transmission.
Discussion
We adapted a classic age-structured population model with
parameters chosen to maximize indirect effects due to vaccinating
older children, adolescents, and young adults, and to accurately
assess direct effects due to vaccinating elderly adults. Comparing
the impact of vaccinating these age groups against influenza, we
found that vaccinating children, adolescents, and young adults
would reduce morbidity the most, with 20–25% of the reduction
in other age groups. However, while vaccinating infants and older
adults would mitigate mortality most during annual outbreaks,
vaccinating young adults also would mitigate mortality during
contemporary 1918-like pandemics.
Evidently, which vaccination strategy is superior depends on the
objective: mitigating morbidity or mortality, and if mortality, its
age-distribution. For many years, U.S. vaccination policy was
designed to mitigate mortality, particularly among elderly adults.
Relatively recently, it was redesigned to also mitigate morbidity,
initially among young children, but then progressively among
older children, adolescents, and adults [http://www.cdc.gov/
media/pressrel/2010/r100224.htm]. Unlike this policy, in which
the 6 month lower age of recommended vaccination has not
changed as the upper age has increased, our experimental design
maintained similar target group sizes by increasing both lower and
upper ages of vaccination simultaneously.
Our findings are comparable to those obtained via other
methodologies. The observation that mortality attributed to
influenza and pneumonia among elderly Japanese was lower
when children were vaccinated routinely [8] suggests that
susceptible young people pose a risk to elderly ones, but not
necessarily directly. While few such studies are unequivocal,
Figure 1. Effective contact or infection rates derived from attack ‘‘rates’’ during the 1957 pandemic [10] and daily contacts
weighted by duration [11].
doi:10.1371/journal.pone.0012777.g001
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Similar conclusions have been reached via community interven-
tion trials [28,29,30] as well as individual-based modeling [9]. As
our findings support results of these studies using other
methodologies, they make a strong case for using relatively simple
population models to examine pressing public health issues, and
therefore to arrive relatively quickly at sound conclusions about
the effectiveness of alternative interventions.
Figure 2. Mortality due to influenza. (a) Ratios of pandemic (1918) and pre-pandemic (1913–1917) mortality rates [13]; (b) rates derived from
deaths attributed to pneumonia and influenza in the United States during 2005 (red), and their product with the ratios above (blue).
doi:10.1371/journal.pone.0012777.g002
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using a variety of modeling approaches and perspectives. In 2007,
Dushoff et al. [31] explored the same strategies in a 2-group model,
one more effective at transmitting the pathogen and other more
vulnerable to its effects. These researchers were reluctant to choose
among the many interesting scenarios described by various
Figure 3. Cases averted by vaccination. Similar patterns in cases averted by vaccinating people aged ,1 year and 65+ years (blue bars), 1–9
years (green bars), 10–19 years (yellow bars), and 20–29 years (red bars) during hypothetical annual (a) and pandemic (b) outbreaks.
doi:10.1371/journal.pone.0012777.g003
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Bansal et al. [32] adopted a more detailed network model with
which they also evaluated these strategies, obtaining results
qualitatively similar to ours. Three years later, Medlock and Galvani
[33] used an age-structured population model with a mixing matrix
whose off-diagonal elements are relatively small [25]. Nonetheless,
they concluded that vaccinating older children, adolescents, and
young adults was the best strategy, regardless of objective.
Figure 4. Deaths averted by vaccination. Dissimilar patterns in deaths averted by vaccinating people aged ,1 year and 65+ years (blue bars), 1–
9 years (green bars), 10–19 years (yellow bars), and 20–29 years (red bars) during hypothetical annual (a) and pandemic (b) outbreaks.
doi:10.1371/journal.pone.0012777.g004
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have been explored recently, by modeling individual members of
socially and spatially structured populations [34–38]. Our work
illustrates several advantages of simpler population models [39].
Insofar as plausible mixing scenarios are modeled, individual
behavior is extraneous. Furthermore, systems of equations can be
analyzed, whereas computer programs cannot; for example, Areno
et al. [40] not only reproduced results with a proportionately-
mixed, age-structured population model that had been obtained
with a relatively complex individual-based model [9], but also
deduced several analytical results. Finally, population models use
observations and make predictions familiar to epidemiologists,
who group individuals based on characteristics of interest, both in
disease surveillance, and to develop and implement interventions.
As recently as 2008, for example, Vynnycky and Edmunds used a
population model to investigate the impact of school closures on
the spread of influenza during a pandemic [41].
Because people of some ages are more active than others,
immunizing those potential ‘‘super-spreaders’’ reduces the average
number of secondary infections disproportionately. As Figure 5
indicates, adolescents and young adults are the optimal targets for
reducing morbidity. Because the main diagonal predominates in
all known mixing matrices [11,23,25,26], however, direct effects
exceed indirect ones. Unless vaccine efficacy is very low,
consequently, the best strategy for reducing mortality will be to
vaccinate members of at-risk groups [42]. This analytical result is
not limited to vaccination; it may be applied to other interventions
that prevent infection or reduce the magnitude or duration of
infectiousness. For example, as neuraminidase inhibitors are most
effective when administered early [43], timely medication of ill
children, adolescents, and young adults could reduce the number
needing treatment and possibly the duration of treatments.
Treating optimally would be much less costly than widespread
prophylaxis, and reduce the risk of drug-resistant strains emerging
[44].
Age-specific infection rates are the essence of population
models. We calculated risks of infection from Chin et al.’s
prospective study of household transmission following illnesses
among schoolchildren [10]; households without school-aged
children were not represented. Together with clinical observations
and individual onset dates, a cross-sectional serological survey
would remedy this possible deficiency and might resolve
uncertainty about the contribution of asymptomatic infections to
transmission. Anderson and May [18] described ‘‘who-acquires-
infection-from-whom’’ matrices with as many unique elements as
risks of infection, but Nold [45] formulated mixing as a convex
combination of age-specific activities (number of contacts per
person per day) and constant preference (proportion with others in
the same group), and Jacquez et al. [46] allowed preference to vary
with age. Recent empirical observations enabled us to include
contacts between parents and children and among co-workers
[Glasser et al. unpublished manuscript]. Insofar as mixing differs
from society to society, if not between rural and urban sub-
populations, more diverse subjects would permit continued
refinement of methods to permit rapid, robust analysis and
interpretation of alternative actions to address public health
priorities.
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